Compositions and methods for detection of hepatitis A virus nucleic acid
View Patent ↗Nucleic acid oligomeric sequences and in vitro nucleic acid amplification and detection methods for detecting the presence of HAV RNA sequences in samples are disclosed. Kits comprising nucleic acid oligomers for amplifying and detecting HAV nucleic acid sequences are disclosed.
1. A combination of at least two oligomers for amplifying a HAV target region comprising:
a first oligomer comprising an HAV target-specific sequence length of 18 to 27 nt contained in the sequence of SEQ ID NO:93; and a second oligomer comprising an HAV target specific sequence comprising the sequence of SEQ ID NO:63, joined at its 5′ end to a promoter sequence.
2. The combination of at least two oligomers of claim 1 , wherein the first oligomer comprises a sequence consisting of: SEQ ID NO:92 or SEQ ID NO:93, and the second oligomer comprises a sequence consisting of SEQ ID NO:33.
3. The combination of at least two oligomers of claim 1 , further comprising at least one capture probe oligomer selected from the group consisting of SEQ ID NOS:1 to 7 and SEQ ID NOS:8-14 linked to a moiety that allows it to bind a solid support.
4. The combination of at least two oligomers of claim 1 , further comprising at least one detection probe oligomer, wherein said detection probe oligomer comprises a nucleotide sequence selected from the group consisting of SEQ ID NO:117, and SEQ ID NO:119.
5. The composition of claim 2 , wherein the first oligomer nucleic acid sequence consists of SEQ ID NO:92 and the second oligomer nucleic acid sequence consists of SEQ ID NO:33.
6. The composition of claim 4 , wherein the detection probe oligomer further comprises at least one 2′ O-methyl linkage.
7. The composition of claim 4 , wherein said detection probe oligomer further comprises a detectable label selected from the group consisting of: a chemiluminescent label, an acridinium ester label, a synthetic linker or combinations thereof.
8. A combination of at least two oligomers for amplifying a HAV target region, wherein said combination is packaged in a kit, said combination comprising:
a first oligomer comprising an HAV target-specific sequence length of 18 to 27 nt contained in the sequence of SEQ ID NO:93; and a second oligomer comprising an HAV target specific sequence comprising the sequence of SEQ ID NO:63, joined at its 5′ end to a promoter sequence.
9. A method of detecting the presence of HAV in a sample comprising the steps of:
purifying HAV nucleic acid from other components in a sample containing HAV;
amplifying a HAV target sequence in the purified HAV nucleic acid, or a cDNA made therefrom, by using an in vitro amplification reaction that includes at least two amplification oligomers specific for a selected HAV target region, which include:
a first oligomer comprising an HAV target specific sequence length of 18 to 27 nt contained in the sequence of SEQ ID NO:93, and a second oligomer comprising an HAV target-specific sequence comprising the sequence of SEQ ID NO:63, joined at its 5′ end to a promoter sequence;
to produce an amplified product of the selected HAV target region; and
detecting the amplified product.
10. The method of claim 9 , wherein the purifying step contacts the sample with at least one capture probe oligomer selected from the group consisting of SEQ ID NOS:1 to 7 and SEQ ID NOS:8-14 linked to a moiety that allows it to bind a solid support, wherein a target hybridization sequence of said at least one capture probe oligomer hybridizes specifically to a sequence in HAV RNA to form a hybridization complex with the HAV RNA, and can be used with a solid support to separate the HAV RNA from other sample components.
11. The method of claim 9 , wherein the amplifying step amplifies a sequence in a fourth HAV target region by using at least two oligomers specific for the fourth HAV target region, wherein the first oligomer comprises a sequence consisting of: SEQ ID NO:92 or SEQ ID NO:93, and the second oligomer comprises a sequence consisting of SEQ ID NO:33; and wherein the detecting step uses at least one detection probe that hybridizes specifically to the amplified product of the fourth HAV target region.
12. The method of claim 9 , wherein said detecting step uses a nucleic acid detection oligomer, wherein said nucleic acid detection oligomer comprises a target hybridizing sequence that specifically hybridizes with at least one amplified product generated in said amplifying step; optionally wherein said nucleic acid detection oligomer comprises a target hybridizing region nucleic acid sequence consisting essentially of a nucleic acid sequence selected from the group consisting of SEQ ID NO:117, and SEQ ID NO:119; optionally wherein said nucleic acid detection oligomer further comprises a 2′-O-methyl linkages, a chemiluminescent label, an acridinium ester label, a synthetic linker or combinations thereof.
13. The method of claim 9 , wherein the sample is a biological sample collected from humans.
14. The method of claim 13 , wherein the sample collected from a human is a plasma sample.
15. The method of claim 13 , wherein the sample collected from a human is a sample used for the preparation of therapeutic factors isolated from humans.
16. The method of claim 9 , wherein the sample collected from a human is a sample used for the preparation of therapeutic factors isolated from humans.
17. The method of claim 16 , further comprising detecting the presence of parvovirus B19 in the sample.
18. The method of claim 9 , further comprising detecting the presence of parvovirus B19 in the sample.
19. The method of claim 9 , wherein the first oligomer nucleic acid sequence consists of SEQ ID NO:92 and the second oligomer nucleic acid sequence consists of SEQ ID NO:33, and wherein the detecting step uses a detection probe oligomer comprising a nucleic acid sequence consisting of SEQ ID NO:117, a detectable label, and at least one 2′ O-methyl residue.